GammaCan Files Additional Patent Applications Covering the Treatment of Malignant Melanoma and Colorectal Cancer with the United

  
    
  
  
    
      GammaCan International Inc.(OTCBB:GCAN), a developer of immunotherapies 
      for cancer and other diseases, today announced that the Company filed 
      two Continuations in Part (CIP) with the U.S. Patent and Trademark 
      Office.
    
    
      The first CIP is titled “Administration of 
      Gamma Globulins to Treat Metastatic Melanoma” 
      and builds on the pre-clinical work conducted at GammaCan and 
      substantiates these findings with data from ongoing clinical trials.
    
    
      The second CIP is titled “Administration of 
      Gamma Globulins to Treat Cancer” and provides 
      experimental data supporting the use of IgG based therapy for colorectal 
      cancers.
    
    
      “These patent filings further strengthen 
      GammaCan’s intellectual property position for 
      the use of IgG based therapies to treat cancers in general, and more 
      specifically, of melanoma and colorectal cancers. Over the past six 
      months we have made progress with our research and clinical programs – 
      we now beginning to see the first fruits of these efforts,” 
      commented Patrick Schnegelsberg CEO.
    
    
      On a Separate matter GammaCan also announced that the Company extended 
      the enrollment period for its GCAN 01 phase II trial to enroll 
      additional patients.
    
    
      About GCAN 01
    
    
      GCAN 01 is an open label, 30 patient phase II trial designed to evaluate 
      the efficacy and safety of IgG therapy in late stage cancer patients who 
      failed all current therapies. The trial is enrolling patients with colon 
      cancer, melanoma and prostate cancer. The colon and melanoma arms are 
      fully enrolled. Data from the melanoma arm was presented at a conference 
      in 2006 and a scientific paper is in press.
    
    
      About GammaCan International, Inc
    
    
      GammaCan is focusing on the commercialization of an innovative 
      anti-cancer immunotherapy to treat metastatic cancer. GammaCan's 
      platform is based on IgG, a safe, relatively non-toxic human 
      plasma-based product, currently used to treat a variety of immune 
      deficiencies and autoimmune diseases. IgG works by strengthening the 
      patient's immune system. Many experts currently view immunotherapy as a 
      future alternative to today's standard chemotherapy. GammaCan is 
      developing VitiGam, its second generation program. VitiGam is an IgG 
      derived from the plasma of vitiligo donors and is being developed to 
      treat malignant melanoma. GammaCan owns, and has applied for US patent 
      protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
    
    
      For more information about GammaCan visit www.GammaCan.com 
      or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 
      738-2616 or toll free 1-866-308-0396 (from North America).
    
    
      Safe Harbor Statement:
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding: the commercialization of an anti-cancer 
      immunotherapy and the Company developing the boosting of cancer 
      patients' immune systems with IVIG into an effective treatment. Actual 
      outcomes and the Company's actual results could differ materially from 
      those in such forward-looking statements. Factors that could cause 
      actual results to differ materially include risks and uncertainties such 
      as the inability to finance the planned development of the technology, 
      inability to hire appropriate staff to develop the technology, 
      unforeseen technical difficulties in developing the technology, 
      inability to obtain regulatory approval for human use, competitors' 
      therapies proving more effective, cheaper or otherwise preferable for 
      consumers, inability to market the product we produce, among other 
      factors, all of which could among other things, delay or prevent product 
      release or cause our company to fail. For further risk factors see the 
      risk factors associated with other early stage medical research and 
      development companies filed with the SEC on Edgar.